Adicet Bio Inc (ACET) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adicet Bio Inc (ACET) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.91 Million) by net assets ($159.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Adicet Bio Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ACET current and long-term liabilities for a breakdown of total debt and financial obligations.
Adicet Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adicet Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
West Vault Mining
V:WVM
|
-0.005x |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
0.013x |
|
BitFuFu Inc. Class A Ordinary Shares
NASDAQ:FUFU
|
0.000x |
|
ktcs corporation
KO:058850
|
0.045x |
|
Jinhui Shipping and Transportation Limited
OL:JIN
|
0.038x |
|
Travelzoo
NASDAQ:TZOO
|
-0.600x |
|
AV Tech Corp
TW:8072
|
-0.020x |
|
Pan-Pacific
KO:007980
|
0.146x |
Annual Cash Flow Conversion Efficiency for Adicet Bio Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Adicet Bio Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Adicet Bio Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.21 Million | $-95.25 Million | -0.598x | -20.85% |
| 2024-12-31 | $186.61 Million | $-92.38 Million | -0.495x | +10.11% |
| 2023-12-31 | $170.18 Million | $-93.72 Million | -0.551x | -259.64% |
| 2022-12-31 | $292.34 Million | $-44.77 Million | -0.153x | +9.08% |
| 2021-12-31 | $303.13 Million | $-51.05 Million | -0.168x | +55.49% |
| 2020-12-31 | $109.83 Million | $-41.55 Million | -0.378x | -181.91% |
| 2019-12-31 | $-60.37 Million | $-27.88 Million | 0.462x | +364.74% |
| 2018-12-31 | $104.20 Million | $-18.18 Million | -0.174x | +24.96% |
| 2017-12-31 | $49.69 Million | $-11.55 Million | -0.232x | -948.40% |
| 2016-12-31 | $304.44 Million | $8.34 Million | 0.027x | -72.20% |
| 2015-12-31 | $254.21 Million | $25.06 Million | 0.099x | -9.63% |
| 2014-12-31 | $233.58 Million | $25.48 Million | 0.109x | -10.55% |
| 2013-12-31 | $194.64 Million | $23.73 Million | 0.122x | +54.37% |
| 2012-12-31 | $168.00 Million | $13.27 Million | 0.079x | -18.90% |
| 2011-12-31 | $144.15 Million | $14.04 Million | 0.097x | +178.13% |
| 2010-12-31 | $124.35 Million | $-15.50 Million | -0.125x | -169.42% |
| 2009-12-31 | $125.38 Million | $22.51 Million | 0.180x | +44.01% |
| 2008-12-31 | $123.67 Million | $15.42 Million | 0.125x | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy express… Read more